Net Loss Per Share

9 Months Ended

Sep. 30, 2022

Earnings Per Share [Abstract]

Net Loss Per Share

Note 16 — Net Loss Per Share

The “Net loss per share - attributable to PAVmed Inc. - basic and diluted” and “Net loss per share - attributable to PAVmed Inc. common stockholders - basic and diluted” - for the respective periods indicated - is as follows:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2022			2021			2022			2021
Numerator
Net loss - before noncontrolling interest	$	(29,932	)	$	(13,668	)	$	(78,666	)	$	(36,447	)
Net loss attributable to noncontrolling interest		3,806			1,441			10,143			3,318
Net loss - as reported, attributable to PAVmed Inc.	$	(26,126	)	$	(12,227	)	$	(68,523	)	$	(33,129	)
Series B Convertible Preferred Stock dividends – earned	$	(71	)	$	(67	)	$	(209	)	$	(216	)
Net loss attributable to PAVmed Inc. common stockholders	$	(26,197	)	$	(12,294	)	$	(68,732	)	$	(33,345	)
Denominator
Weighted average common shares outstanding, basic and diluted		89,758,927			83,307,170			87,724,124			79,873,583
Net loss per share
Basic and diluted
Net loss - as reported, attributable to PAVmed Inc.	$	(0.29	)	$	(0.15	)	$	(0.78	)	$	(0.41	)
Net loss attributable to PAVmed Inc. common stockholders	$	(0.29	)	$	(0.15	)	$	(0.78	)	$	(0.42	)

The common stock equivalents have been excluded from the computation of diluted weighted average shares outstanding as their inclusion would be anti-dilutive, are as follows:

The Series B Convertible Preferred Stock dividends earned as of each of the respective periods noted, are included in the calculation of basic and diluted net loss attributable to PAVmed Inc. common stockholders for each respective period presented. Notwithstanding, the Series B Convertible Preferred Stock dividends are recognized as a dividend payable only upon the dividend being declared payable by the Company’s board of directors.

Basic weighted-average number of shares of common stock outstanding for the periods ended September 30, 2022 and 2021 include the shares of the Company issued and outstanding during such periods, each on a weighted average basis. The basic weighted average number of shares of common stock outstanding excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes such incremental shares. However, as the Company was in a loss position for all periods presented, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive. The common stock equivalents excluded from the computation of diluted weighted average shares outstanding are as follows:

	September 30,
	2022		2021
Stock options and restricted stock awards		12,586,571		10,214,448
Series Z Warrants		11,937,450		13,887,814
Series W Warrants		—		377,873
Series B Convertible Preferred Stock		1,182,101		1,091,448
Total		25,706,122		25,571,583

The total stock options and restricted stock awards are inclusive of 500,854 stock options as of September 30, 2022 and 2021; and 100,000 restricted stock awards as of September 30, 2022, granted outside the PAVmed Inc. 2014 Equity Plan.